Biotech start-up pockets $8.7M in venture cash
Cellumen says it will use an $8.7 million injection of venture capital to begin its commercialization efforts. The company specializes in cellular systems biology for drug discovery work. Safeguard Scientifics provided $6 million of that while PA Early Stage Partners put up $2 million.
- see the release
- read the the Pittsburgh Business Journal report
Related Articles:
Biotech start-ups flush from big venture rounds. Report
Biotech venture funding jumped in '06. Report
Be the first to comment
More stories about Venture Capital
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
